BeLAB21/22 BRIDGE
Mediated and supported by bioRN, Evotec established in 2021 the beLAB2122 BRIDGE. With 20M Euro Fund for preclinical development of academic drug discovery projects, beLAB2122 is a new public-private partnership between the leading academic institutions of the Rhine-Neckar region, Evotec and Bristol Myers Squibb to identify, fund and execute novel disease modifying therapeutic projects with the goal to develop these to new spinout companies.
tester